Transparency Matters: A Shift in the Right Direction
- outreach0686
- Jun 2
- 2 min read
🩺 Transparency Matters: New Senate Report and FDA Booster Policy Signal a Shift
Toward Evidence-Based, Patient-Centered Care
As physicians who stood firm during the pandemic—advocating for open dialogue, scientific integrity, and truth over fear—I want to share two important developments that underscore why questioning the narrative is not only reasonable, but essential to science and public trust.
🧬 1. Senate Report: Myocarditis Risks Downplayed
A newly released Senate interim report, led by Sen. Ron Johnson (R-WI), reveals troubling findings: federal health officials were aware of elevated risks of myocarditis and pericarditis—inflammation of the heart—following mRNA COVID-19 vaccination, yet allegedly delayed formal public warnings.
The 55-page report, based on over 2,400 pages of subpoenaed documents, shows that as early as February 2021, U.S. agencies like HHS, CDC, and FDA had received warnings from Israeli health officials about rising myocarditis rates in young adults, particularly males aged 16–24. Internal discussions in April and May acknowledged these safety signals, yet a formal public health alert was never issued. Instead, limited guidance was quietly posted to the CDC website, and vaccine labels were not updated until late June 2021.
"Rather than provide the public and healthcare providers with immediate and transparent information… the administration opted to withhold issuing a formal warning to the public for months… jeopardizing the health of young Americans."
This delay in communication is deeply concerning. It highlights the need for unwavering commitment to informed consent, data transparency, and scientific humility—the cornerstones of ethical medicine.
📄 You can read the full Senate Interim Report here:
🩹 2. FDA’s New Booster Guidelines Affirm Vaccine Choice
In a promising step toward evidence-based decision-making, the FDA has announced updated guidelines for COVID-19 booster approvals. Going forward, annual boosters for healthy individuals ages 6 months to 64 years will require randomized controlled trials to receive FDA authorization.
This move affirms the importance of rigorous science and aligns the U.S. with global health standards. Importantly, high-risk groups, such as individuals aged 65+ or those with chronic conditions, will continue to have access to updated boosters based on immune response data.
As FDA Commissioner Marty Makary and vaccine advisor Vinay Prasad noted:
“We simply don’t know whether a healthy 52-year-old woman with a normal BMI who has had COVID-19 three times and six vaccine doses benefits from a seventh.”
This policy acknowledges the evolving science, respects personal health histories, and supports individualized medical decisions. It’s a shift away from one-size-fits-all mandates and toward restoring medical autonomy—something we have long championed.
📖 Full article available here:
Let us continue to speak boldly for a healthcare system rooted in trust, transparency, and patient-first ethics. Medical freedom and evidence-based care are not opposing values—they must go hand in hand.
🙏 Thank you for standing with us.
Comments